What Principia Biopharma Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Becker Daniel J. | Director | Sep 28 | Tender Offer · U | −667,600 | $100.00 | −$66.8M | 0 |
| George Simeon | Director | Sep 28 | Tender Offer · U | −2,982,855 | $100.00 | −$298M | 0 |
| Hardiman Roy C. | Chief Business Officer | Sep 28 | Tender Offer · U | −1,916 | $100.00 | −$192K | 0 |
| Hardiman Roy C. | Chief Business Officer | Sep 28 | Tender Offer · U | −117,761 | $100.00 | −$11.8M | 0 |
| Chai Christopher Y | Chief Financial Officer | Sep 28 | Tender Offer · U | −3,302 | $100.00 | −$330K | 0 |
| Chai Christopher Y | Chief Financial Officer | Sep 28 | Tender Offer · U | −3,799 | $100.00 | −$380K | 0 |
| Babler Martin | President, CEO | Sep 28 | Tender Offer · U | −18,355 | $100.00 | −$1.84M | 0 |
| Babler Martin | President, CEO | Sep 28 | Tender Offer · U | −39,179 | $100.00 | −$3.92M | 0 |
| Babler Martin | President, CEO | Sep 28 | Tender Offer · U | −1,023 | $100.00 | −$102K | 0 |
| Goldstein David | Chief Scientific Officer | Sep 28 | Tender Offer · U | −31,826 | $100.00 | −$3.18M | 0 |
| Thomas Dolca | Chief Medical Officer | Sep 28 | Tender Offer · U | −2,207 | $100.00 | −$221K | 0 |
| Wolff Stefani | Chief Development Officer | Sep 28 | Tender Offer · U | −13,592 | $100.00 | −$1.36M | 0 |
| Hardiman Roy C. | Chief Business Officer | Sep 18 | Open-market sale · S | −5,000 | $99.98 | −$500K | 117,761 |
| Hardiman Roy C. | Chief Business Officer | Sep 18 | Exercise / conversion · M | +2,242 | $7.27 | +$16.3K | 122,761 |
| Hardiman Roy C. | Chief Business Officer | Sep 18 | Exercise / conversion · M | +2,758 | $4.72 | +$13K | 120,519 |
| Wolff Stefani | Chief Development Officer | Sep 18 | Gift · G | −5,504 | — | — | 13,592 |
| Chai Christopher Y | Chief Financial Officer | Aug 18 | Open-market sale · S | −7,500 | $99.37 | −$745K | 3,539 |
| Chai Christopher Y | Chief Financial Officer | Aug 18 | Exercise / conversion · M | +7,500 | $3.00 | +$22.5K | 11,039 |
| Thomas Dolca | Chief Medical Officer | Aug 18 | Open-market sale · S | −15,000 | $100.00 | −$1.5M | 1,826 |
| Thomas Dolca | Chief Medical Officer | Aug 18 | Exercise / conversion · M | +15,000 | $23.77 | +$357K | 16,826 |
Loading...
